混合纳米粒子 - 免疫细胞结合剂用于增强抗癌疗效
Ashok Kumar Jangid1, Sungjun Kim1, Kyobum Kim1
1Department of Chemical & Biochemical Engineering, College of Engineering, Dongguk University, Seoul, South Korea.
Colloids and surfaces. B, Biointerfaces
|October 2, 2025
概括
纳米粒子-细胞结合物 (NCC) 通过编程免疫细胞以更好地向瘤来增强癌症免疫疗法. 这种模块化方法为下一代疗法提供了基因工程的有希望的替代方案.
科学领域:
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
- 材料科学 材料科学 材料科学
背景情况:
- 基于细胞的疗法,包括CAR-T和CAR-NK细胞,在癌症免疫治疗中至关重要.
- 使用纳米颗粒的细胞表面工程为调节免疫细胞功能提供了一个补充策略.
研究的目的:
- 审查纳米粒子-细胞结合体 (NCC) 开发用于癌症免疫疗法的关键方面.
- 探索纳米粒子设计,结合策略,局限性以及人工智能在NCC中的作用.
主要方法:
- 讨论各种细胞表面工程技术:疏水插入,共价结合,糖工程,直角化学和宿主-客体相互作用.
- 分析纳米粒子设计标准和NCC策略的可编程相互作用和受控释放.
- 检查当前直接结合方法的局限性.
主要成果:
- 纳米粒子-细胞结合物使可编程相互作用,可控释放和增强瘤向成为可能.
- 目前的结合方法面临着细胞活力和体受体特异性的挑战.
- 人工智能 (AI) 在设计先进的基于细胞的疗法方面显示出潜力.
结论:
- 纳米粒子-细胞结合体代表了下一代癌症免疫治疗中基因工程的模块化和有前途的替代方案.
- 国家免疫中心扩大治疗工具包,用于开发先进的免疫疗法.
相关概念视频
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
01:31Hybridoma Technology
17.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.3K